Comparative Pharmacology
Head-to-head clinical analysis: CYCLACILLIN versus MUPIROCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLACILLIN versus MUPIROCIN.
CYCLACILLIN vs MUPIROCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Mupirocin reversibly binds to bacterial isoleucyl-tRNA synthetase, inhibiting protein synthesis.
250-500 mg orally every 6 hours.
Apply a small amount of 2% ointment or cream to affected area three times daily for 5 to 14 days.
None Documented
None Documented
0.5–1 hour in adults with normal renal function; prolonged to 10–15 hours in anuria.
Intravenous: ~30 min (0.5 h). Topical: systemically absorbed amount negligible, local half-life not defined.
Clinical Note
moderateCyclacillin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cyclacillin."
Clinical Note
moderateCyclacillin + Mycophenolic acid
"The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Cyclacillin resulting in a loss in efficacy."
Clinical Note
moderateCyclacillin + Plicamycin
"The serum concentration of Plicamycin can be decreased when it is combined with Cyclacillin."
Clinical Note
moderatePrimarily renal (90%) as unchanged drug via glomerular filtration and tubular secretion; negligible biliary/fecal elimination (<5%).
Renal: <1% unchanged (topical); hepatic metabolism to monic acid, eliminated renally and fecally. After IV administration, 60-70% renal, 20-30% fecal/biliary.
Category C
Category A/B
Antibiotic
Antibiotic
Cyclacillin + Valrubicin
"The serum concentration of Valrubicin can be decreased when it is combined with Cyclacillin."